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Key Points
 Adaptation to hypoxia makes the heart more oxygen efficient, by metabolising more
glucose. In contrast, type 2 diabetes does the opposite, making the heart metabolise
more fatty acids.
 Diabetes increases the chances of the heart being exposed to hypoxia, but whether the
diabetic heart can respond is unknown.
 In this study we show that diabetic hearts retain the ability to adapt their metabolism in
response to hypoxia, with functional hypoxia signalling pathways.
 However, the hypoxia-induced changes in metabolism are additive to abnormal baseline
metabolism, resulting in hypoxic diabetic hearts metabolising more fat and less glucose
than controls. This stops the diabetic heart being able to recover its function when
stressed.
 These results demonstrate the diabetic heart retains metabolic flexibility to adapt to
hypoxia, but is hindered by the baseline effects of the disease. This increases our
understanding of how the diabetic heart is affected by hypoxia-associated complications
of the disease.
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Abstract
Hypoxia activates the hypoxia-inducible factor (HIF), promoting glycolysis and suppressing mitochondrial
respiration. In the type 2 diabetic heart, glycolysis is suppressed whereas fatty acid metabolism is promoted.
The diabetic heart experiences chronic hypoxia as a consequence of increased obstructive sleep apnoea and
cardiovascular disease. Given the opposing metabolic effects of hypoxia and diabetes, we questioned
whether diabetes affects cardiac metabolic adaptation to hypoxia.
Control and type 2 diabetic rats were housed for three weeks in normoxia or 11% oxygen. Metabolism and
function were measured in the isolated perfused heart using radiolabelled substrates. Following chronic
hypoxia, both control and diabetic hearts upregulated glycolysis, lactate efflux and glycogen content and
decreased fatty acid oxidation rates, with similar activation of HIF signalling pathways. However, hypoxia-
induced changes were superimposed on diabetic hearts that were metabolically abnormal in normoxia,
resulting in glycolytic rates 30% lower, and fatty acid oxidation 36% higher in hypoxic diabetic hearts than
hypoxic controls.  Peroxisome proliferator-activated receptor α target proteins were suppressed by hypoxia 
but activated by diabetes. Mitochondrial respiration in diabetic hearts was divergently activated following
hypoxia compared with controls. These differences in metabolism were associated with decreased
contractile recovery of the hypoxic diabetic heart following an acute hypoxic insult.
In conclusion, type 2 diabetic hearts retain metabolic flexibility to adapt to hypoxia, with normal HIF
signalling pathways. However, they are more dependent on oxidative metabolism following hypoxia due to
abnormal normoxic metabolism, which was associated with a functional deficit in response to stress.
Abbreviations: FAT/CD36, fatty acid translocase; GLUT, glucose transporter; HIF, hypoxia-
inducible factor; MCAD, medium chain acyl-coenzyme A dehydrogenase; PDK, pyruvate dehydrogenase
kinase; PPARα, peroxisome proliferator-activated receptor α; UCP, uncoupling protein    
Hypoxia-induced metabolism in the diabetic heart
4
Introduction
The healthy heart can metabolise a range of substrates to meet its high energy requirements, including fatty
acids, glucose, lactate, ketone bodies and amino acids (Taegtmeyer et al., 2004). Fatty acids are a more
energy dense fuel, providing more ATP per carbon, and account for 60-70% of ATP production, whereas
glucose is a more oxygen-efficient fuel able to provide ATP via anaerobic glycolysis (Bing et al., 1954; van
der Vusse et al., 1992). In contrast to the healthy heart, in type 2 diabetes the heart becomes metabolically
abnormal, oxidising more fatty acids and metabolising less glucose, which is associated with increased
myocardial oxygen consumption independent of contraction (Jagasia et al., 2001; Peterson et al., 2004;
Boardman et al., 2009).
A fine balance exists between the supply of and the demand for oxygen within the heart. A decrease in
cellular oxygen availability, hypoxia, causes the transcription factor hypoxia-inducible factor (HIF)1α to 
escape degradation, translocate to the nucleus and induces transcription of HIF-target genes, which over a
period of days to weeks regulate a plethora of cellular processes aimed at optimising utilisation of the
available oxygen and restoring oxygen supply (Semenza, 2009). Hypoxia and HIF activation have profound
effects on cardiac metabolism, increasing anaerobic glycolysis and suppressing mitochondrial oxidative
metabolism (Semenza et al., 1994; Ebert et al., 1995; Kim et al., 2006; Fukuda et al., 2007; Ambrose et al.,
2014). Thus, hypoxia and HIF activation are major metabolic regulators of substrate selection in the heart,
making the heart more oxygen efficient under hypoxic conditions. From a metabolic perspective, type 2
diabetes and hypoxia have opposite effects on cardiac metabolism. Type 2 diabetes promotes fatty acid
metabolism and mitochondrial oxygen consumption, whereas HIF activation promotes glycolysis and
suppresses mitochondrial respiration (Semenza et al., 1994; Boardman et al., 2009; Ambrose et al., 2014).
Therefore, we questioned what would happen when a diabetic heart was exposed to hypoxia, and whether
the diabetic heart retains the ability to adapt its metabolism to hypoxia given its preference for fatty acids.
Type 2 diabetes is accompanied by a number of hypoxia-associated complications, which result in
cardiomyocytes being exposed directly or indirectly to hypoxia. Systemically, type 2 diabetes increases the
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incidence of obstructive sleep apnoea, which is a risk factor for cardiovascular disease and mortality, and
there is a negative relationship between the severity of sleep apnoea and insulin sensitivity (Meslier et al.,
2003; West et al., 2006; Tasali et al., 2008). The Sleep Heart Health Study identified an increased incidence
of periodic breathing during sleep in type 2 diabetics, and a systematic review identified an association
between type 2 diabetes and decreased lung function (Resnick et al., 2003; Klein et al., 2010). Type 2
diabetes increases the risk of having a myocardial infarction and developing heart failure, and following
myocardial infarction mortality rates are increased among diabetic patients (Rytter et al., 1985; Almdal et
al., 2004; Shah et al., 2015). Following myocardial infarction, cardiac ischemia reduces cellular oxygen
availability within the cardiomyocyte and activates hypoxic signalling pathways within the myocardium,
and HIF signalling persists chronically in the peri-infarct region of the heart (Lee et al., 2000; Willam et al.,
2006). Thus, diabetes is associated with a greater incidence of the heart experiencing chronic hypoxia, and,
whether this is via a direct or indirect mechanisms, it is associated with negative consequences for the
diabetic heart. Therefore, important questions remain as to how the diabetic heart adapts when challenged
by chronic hypoxia.
Conflicting data has been generated on the effects of diabetes on the cardiac HIF signalling pathway, with
some studies showing HIF1α as increased, decreased or unchanged (Marfella et al., 2002; Marfella et al.,
2004; Park et al., 2009; Xue et al., 2012).  However, these studies have looked at HIF1α in normoxia or 
ischemia, studies have not been performed looking at HIF signalling and downstream effects using the
transcription factors endogenous activator, hypoxia. Using a normobaric hypoxia chamber we can study
how the diabetic heart metabolically adapts to chronic hypoxia and the effects of diabetes on activation of
the HIF signalling pathway, which would not be possible in the isolated organ or tissue culture. Here, we
demonstrate that type 2 diabetic hearts retain the capacity to upregulate glycolysis and glycogen content by
the same percentage as control hearts, and that the HIF signalling pathway is not compromised. However,
the adaptation to hypoxia in diabetes is superimposed on an abnormal metabolic fuel preference at normoxic
baseline. This result in the diabetic heart having lower rates of anaerobic glycolysis and higher rates of
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oxidative metabolism then control hearts following chronic hypoxia, and is associated with a decreased
recovery following an acute hypoxic insult.
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Methods
In vivo rat model of type 2 diabetes and chronic hypoxia
Ethical approval for experiments was granted by the United Kingdom Home Office guidelines under The
Animal (Scientific Procedures) Act, 1986 after approval by the University of Oxford local ethics committee.
Male Wistar rats (n = 73) were obtained from a commercial breeder (Harlan, UK). Control rats were fed for
42 days ad libitum on a standard chow diet (Harlan Laboratories). To induce type 2 diabetes, rats were fed
a high-fat diet ad libitum (Special Diet Services) for 42 days, according to our previously published protocol
(Mansor et al., 2013a). On day 14 of 42, diabetic rats were given a single intraperitoneal injection of low
dose streptozotocin (STZ, 25mg/kg bodyweight w/w in citrate buffer, pH 4). We have previously
demonstrated that it is the combination of high-fat diet and STZ that induces diabetes, and that either factor
in isolation is not sufficient to induce disease (Mansor et al., 2013a). On day 20, control and diabetic rats
had fasting blood collected from the saphenous vein for blood glucose analysis (Accu-check Aviva blood
glucose testing system) and for plasma insulin concentrations (ELISA, R&D systems), to confirm
hyperglycaemia and hyperinsulinemia in the diabetic animals prior to hypoxia. On day 21, subgroups of
control and diabetic rats were transferred to a normobaric hypoxia chamber (Biospherix) (Heather et al.,
2012), while the remaining rats continued to be housed in normoxia. From days 21 to 28, the oxygen content
in the hypoxia chamber was reduced from 21% to 11% in daily steps, which produced physiological hypoxic
adaptation and prevented weight loss. From days 28 to 42, the oxygen content was maintained at 11%.
Following hypoxia or normoxia, rats were terminally anaesthetised under normoxia, using an intraperitoneal
injection of sodium pentobarbital, hearts were excised and blood collected for analysis. Due to Home Office
restrictions, hearts could not be excised whilst the animals were still hypoxic.
Isolated heart perfusion
Hearts were perfused at a constant pressure of 100 mmHg and an end-diastolic pressure of 4-8 mmHg,
according to our published protocol (Heather et al., 2013). Hearts were perfused with Krebs-Henseleit buffer
containing 11 mM glucose, 0.3 U/L insulin and 1.5% (w/v) fatty acid-free bovine serum albumin bound to
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0.4 mM palmitate (gassed with 95% O2 and 5% CO2, at 37oC). For measurement of palmitate oxidation
rates, buffer was supplemented with 0.2 µCi.ml-1 [9,10-3H] palmitate, and for measurement of glycolytic
rates buffer was supplemented with 0.2 μCi.ml-1 [5-3H]-glucose. Lactate efflux rates were measured in timed
aliquots using lactate dehydrogenase. Metabolic rates were expressed per gram wet weight of tissue (gww).
In a separate group of chronically hypoxic hearts, the oxygen partial pressure (pO2) of the buffer was reduced
from 413 ± 15 mmHg to 90 ± 10 mmHg for 32 minutes, by replacing the gas supply with 95% N2 and 5%
CO2. This was followed by 8 minutes of reoxygenation at the original oxygen partial pressure, to study the
recovery of function following an acute hypoxic insult.
Mitochondrial isolation and respiration
Mitochondria were isolated from hearts, according to our previously published protocol (Heather et al.,
2012). Mitochondria were incubated in respiratory media (100 mM KCl, 50 mM MOPS, 1 mM EGTA, 5
mM KH2PO4 and 1 mg/ml BSA, pH 7.4), and respiration was measured using a Clark-type oxygen electrode
with a range of substrates (Heather et al., 2012). State 3 (100 nmol ADP-stimulated) respiration, state 4
(ADP-limited) respiration, maximal ADP-stimulated (1000 nmol) respiration (max ADP), and respiratory
control ratios (RCR, state 3/state 4 respiration rates) were measured at 30oC.
Tissue analysis
Tissue assays were performed on freeze clamped tissue. Glycogen content was determined by the
conversion of glycogen to glycosyl units, using amyloglucosidase. Triglyceride content was measured
following Folch extraction. Citrate synthase activity, a marker of mitochondrial number, aconitase activity
and medium chain acyl-coenzyme A dehydrogenase (MCAD) activity were measured according to
established protocols (Srere, 1969; Lehman et al., 1990).
Metabolomics
Aqueous metabolites were extracted using methanol/water/chloroform extraction protocol from freeze-
clamped hearts and quantified using high resolution 1H nuclear magnetic resonance spectroscopy (Mayr et
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al., 2008). Chemical shifts and metabolite peak areas were calibrated against trimethylsilyl propanoic acid
reference peak (3 µM) at pH 6.5 and normalized for gww of tissue extracted (Tyagi et al., 1996).
Western blotting
Protein lysates were prepared, 30µg of protein was loaded onto 12.5% SDS-PAGE gels and separated by
electrophoresis (Heather et al., 2006). Even protein loading and transfer were confirmed by Ponceau
staining and using cyclophilin B as an internal standard. Bands were quantified using UN-SCAN-IT gel
software (Silk Scientific, USA), and all samples were run in duplicate on separate gels to confirm results.
For measurement of HIF1α protein levels, tissue lysates were compared to HL1 cardiomyocytes cultured in 
2% oxygen for 6 hours (Ambrose et al., 2014), to act as a positive control.
Real-time quantitative PCR
Left ventricular tissue was immersed in RNAlater (Qiagen, Germany), and total RNA was extracted
according to the RNeasy Fibrous Tissue kit Protocol (Qiagen, Norway). Real-time PCR (qPCR) was
performed in an ABI PRISM 7900 HT fast real-time thermal cycler as previously described (Hafstad et al.,
2009). Housekeeping genes were selected on the basis of the average expression stability determined with
Genorm from a pool of five candidate genes (Vandesompele et al., 2002), and mRNA expression of the
genes of interest was adjusted to the geomean of the three most stable housekeeping genes. Real-time
quantitative PCr was performed for heme oxygenase 1 (NM_012580.2), vascular endothelial growth factor
(VEGF; NM_031836.2), prolyl hydroxylase 3 (NM_019371.1), HIF1α (NM_024359.1), glyceraldehyde-3-
phosphate dehydrogenase (NM_017008), ribosomal protein L13A (NM_173340.2) and
hydroxymethylbilane synthase (NM_013168.2).
Statistics
Results are presented as means ± SEM, and were considered significant at p < 0.05 (SPSS Statistics 18).
Differences were investigated using a two-way ANOVA (two factors were diabetic status and oxygen
level), and interactions are reported where identified. Only if statistical significance was obtained at the
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ANOVA level were subsequent post-hoc individual comparison between groups performed using unpaired
t-tests.
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Results
Physical characteristics and plasma metabolites
There were no significant differences in body weights between groups (Table 1). Hypoxia had no effects on
heart weights or epididymal fat pad weights, but both measurements were increased by diabetes. Fasting
plasma metabolites were measured in control and diabetic rats prior to entry into the hypoxia chamber, to
confirm their diabetic status. Type 2 diabetic rats had 31% higher fasting blood glucose concentrations and
42% higher fasting plasma insulin concentrations compared with controls. Plasma metabolites were also
measured following a three weeks in normoxia or hypoxia. In response to hypoxia, glucose concentrations
were reduced by 18-20% in controls and diabetics, resulting in the amelioration of the hyperglycaemia in the
diabetic rats. NEFA and TAG were increased by hypoxia in both groups, with the former also increased by
diabetes. There was a significant effect of hypoxia on plasma insulin concentrations, with hypoxic diabetic
rats having 41% lower insulin concentrations than normoxic diabetic rats. Interestingly, there was a
significant interaction between diabetes and hypoxia on plasma β-OHB concentrations, which were elevated 
to a greater extent by hypoxia in diabetic rats than in controls.
Cardiac function
There was a significant interaction between hypoxia and diabetes for their effects on coronary flow rates,
with diabetic rat hearts having significantly greater coronary flow rates following hypoxia, 25% higher than
controls (Table 2). Rate pressure product, the multiple of developed pressure and heart rate, was not
significantly different between groups, demonstrating that overall cardiac systolic function was not modified
by diabetes or adaptation to chronic hypoxia.
Glucose metabolism
Exposure to chronic hypoxia increased cardiac glycolytic rates by 25% in both control and type 2 diabetic
rats. However, diabetes had a significant opposing effect on glycolysis reducing rates by a third, resulting
in a 30% lower rate of anaerobic glycolysis in hypoxic diabetics compared with hypoxic controls (Figure 1).
The changes in cardiac glycolytic rates were reflected by changes in net lactate efflux from these hearts.
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Hypoxia increased cardiac glycogen content by 24 and 20% in control and diabetic rats, respectively, but
diabetes had a significant negative effect on glycogen content, resulting in hypoxic diabetic hearts having
18% lower glycogen content compared with hypoxic controls, mirroring the changes in glycolytic flux.
Fatty acid metabolism
Hypoxia and diabetes had opposing effects on fatty acid oxidation, with hypoxia decreasing and diabetes
increasing cardiac fatty acid oxidation rates. As a consequence, diabetic rats oxidised 31% more fatty acid
than controls in normoxia, and 36% more fatty acids than controls following hypoxia (Figure 2). These
changes in fat oxidation were independent of significant changes in intracellular triglycerides. Citrate
synthase activity, a marker of mitochondrial content, showed a similar profile to fatty acid oxidation rates,
remaining significantly increased in hypoxic diabetic rats compared with hypoxic controls.
Changes in intracellular energy metabolism and substrate availability were further investigated using
metabolomics (Table 3). Hypoxia decreased total creatine concentrations, with hypoxic diabetic hearts
having 20% less creatine compared with normoxic diabetics. Krebs cycle intermediates, multiple amino
acids and NAD+, a marker of the redox state of the heart, were unchanged between groups. However,
aspartate concentrations were increased by diabetes, with hypoxic diabetic hearts having 77% more aspartate
compared with hypoxic controls.
Mitochondrial respiration
The higher coronary flow rates and fatty acid oxidation rates in hypoxic diabetic rat hearts compared with
hypoxic control hearts would suggest increased rates of mitochondrial oxygen consumption. To test this
hypothesis, oxygen consumption was measured in isolated interfibrillar (IFM) and subsarcolemmal (SSM)
mitochondria. There was a significant interaction between diabetes and hypoxia on oxygen consumption in
IFM and SSM when metabolising the fatty acid substrate palmitoyl CoA (Figure 3). Chronic hypoxia
decreased state 3 respiration in mitochondria from control hearts by 28 and 25%, in IFM and SSM
respectively. In contrast, this effect of chronic hypoxia was absent in mitochondria from diabetic hearts, as
diabetes prevented the decrease in state 3 respiration in response to hypoxia. State 4 respiration, a measure
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of oxidative phosphorylation-independent oxygen consumption, also displayed a significant interaction
between diabetes and hypoxia. Whereas hypoxia had no effect on succinate state 4 respiration in IFM from
control hearts, in diabetic hearts hypoxia significantly increased state 4 respiration rates by 53% compared
with hypoxic controls. Thus, diabetes prevented the fatty acid-dependent decrease in state 3 respiration, and
exacerbated the ATP-independent consumption of oxygen by the mitochondria following hypoxia.
Normal HIF-1α signalling pathways in type 2 diabetic hearts in response to hypoxia
The adaptation to chronic hypoxia is regulated by the HIF1α pathway, and there have been reports that HIF 
signalling is perturbed in diabetes. However, we hypothesised that the HIF signalling pathway was not
disrupted in our model of type 2 diabetes, given that our diabetic animals were able to increase their cardiac
glycolytic and lactate efflux rates by the same percentage as controls following hypoxia.
Haematocrits were increased by hypoxia to the same extent in control and diabetic animals, demonstrating
no systemic defect in hypoxic sensing or signalling in diabetes (Figure 4).  Cardiac HIF-1α mRNA was not 
different between any of the groups. Downstream targets of HIF signalling, prolyl hydroxylase 3 and heme
oxygenase 1 were both increased in hypoxia to a similar extent in control and diabetic rat hearts. In addition,
aconitase activity, a metabolic HIF target (Ambrose et al., 2014), was decreased to the same extent by
hypoxia in control and diabetic hearts. Cardiac VEGF mRNA showed no difference between control and
diabetic rats.  Finally, HIF-1α protein was not detected in normoxic diabetic or control hearts.  Taken as a 
whole, these data demonstrate no prior abnormality in the HIF signalling pathway due to type 2 diabetes,
and no abnormalities in the HIF-induced signals following hypoxia.
Overactivation of PPARα signalling in type 2 diabetes following hypoxia  
Despite seeing similar percentage changes in fatty acid oxidation and glycolysis in response to hypoxia in
diabetic and control rats, the absolute rates of metabolism through these two pathways remained significantly
different between controls and diabetics following hypoxia. We hypothesised that this was due to the
abnormal baseline normoxic metabolism, onto which the hypoxic response was superimposed. We
questioned whether there was inappropriate activation of the key metabolic transcription factor, peroxisome
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proliferator-activated receptor (PPAR) α, which maintained the hypoxic diabetic heart in a more fatty acid 
oxidative state and requiring greater oxygen consumption than the hypoxic control heart. To test this
hypothesis we measured PPARα-targets: pyruvate dehydrogenase kinase 4 (PDK4), uncoupling protein 3 
(UCP3), medium chain acyl-coenzyme A dehydrogenase (MCAD) and fatty acid transport protein 1
(FATP1).
Hypoxia and diabetes had opposing effects on PPARα targets, with hypoxia decreasing and diabetes 
increasing PPARα target proteins.  PPARα targets were decreased by hypoxia, with significant decreases 
ranging from 20 - 34% in control hearts (Figure 5), and this was independent of a decrease in PPARα mRNA.  
PPARα targets PDK4, UCP3 and MCAD were all significantly upregulated by diabetes, ranging from a 30% 
to a 2 fold increase compared with controls.  As a result, PPARα target proteins in hypoxic diabetic hearts 
were between 24% higher and 3 fold higher than in hypoxic control hearts. To confirm that these changes
were specific to PPARα targets we measured protein levels of two metabolic proteins that are not direct 
PPARα targets, and found both GLUT4 and FAT/CD36 were modified by diabetes but not by hypoxia.  
Increased PPARα target enzymes would facilitate the increased fatty acid oxidation and mitochondrial 
oxygen consumption in hypoxic diabetic rat hearts, and via the Randle cycle would suppress glucose uptake
and limit glycolysis, glycogenesis and lactate efflux (Randle et al., 1963), providing a mechanism to account
for metabolic changes following hypoxia in our type 2 diabetic hearts.
Decreased recovery of the diabetic heart following acute hypoxia
Diabetic hearts retained the ability to adapt to hypoxia, but the metabolic profile was more oxidative and less
glycolytic than control heart following hypoxia. Therefore, we questioned whether this adaptation to
hypoxia in the diabetic heart was sufficient for the heart to tolerate an acute hypoxic insult to the same extent
as a hypoxic control heart. Cardiac function was the same in both groups when perfused in normoxia (Table
2). Cardiac function decreased to a greater percentage in diabetic hearts at the start of the acute hypoxic
insult, and did not recovery to the same percentage following reoxygenation (Figure 6). Whereas control
hearts recovered 101% of their pre-hypoxic rate pressure product, diabetic hearts only recovered 85%.
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Therefore, diabetic hearts had an impaired functional response to acute hypoxia when compared to control
hearts, when both had been acclimatised to chronic hypoxia.
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Discussion
In this study we demonstrate that in response to chronic hypoxia, type 2 diabetic rats retain the ability to
adapt their cardiac metabolism, by increasing anaerobic glycolysis and glycogen content by a similar
percentage to control hearts.  In addition, the HIF1α signalling pathway was preserved in diabetic hearts, and 
similarly activated by hypoxia in control and diabetic rats. However, in diabetes the hypoxia-induced
changes in energy metabolism were superimposed on the abnormal metabolic state present in normoxia.
This resulted in lower absolute rates of glycolysis, glycogen content and higher absolute rates of fatty acid
oxidation and mitochondrial oxygen consumption following hypoxia in diabetic hearts compared with
control hearts.  Hypoxia and diabetes had opposing effects on PPARα target proteins, resulting in proteins 
involved in oxidative fatty acid metabolism being higher in hypoxic diabetic hearts than in controls.
Mitochondrial respiration rates and coronary flow rates showed divergent responses in controls and diabetic
hearts when exposed to chronic hypoxia. These differences in energy metabolism between control and
diabetics following chronic hypoxia were associated with negative functional outcomes when challenged
with an acute hypoxic insult, with diabetic hearts recovering less contractile function than controls.
Diabetes and hypoxia have opposing effects on cardiac substrate metabolism, as diabetes promotes fatty acid
oxidation and suppresses glycolysis, whereas adaptation to hypoxia suppresses fatty acid oxidation and
promotes glycolysis. Thus, diabetes and hypoxia sit at either end of a metabolic “see-saw”, and it was
important to understand what happens metabolically when both diabetes and hypoxia stimuli are present.
From a clinical perspective being able to adapt to hypoxia is important for the diabetic heart, as diabetes
makes the heart to be more likely to experience hypoxia, either indirectly due to obstructive sleep apnoea,
impaired lung function, or directly via chronic cardiac disease (West et al., 2006; Klein et al., 2010; Shah et
al., 2015). Therefore, understanding if the diabetic heart can adapt to hypoxia and the metabolic
consequences, are important for understanding the effects and consequences of these diseases.
Adaptation to hypoxia involves manipulating metabolism from a more fatty acid oxidative to a more
glycolytic phenotype to ensure essential ATP generation can continue in oxygen-restricted conditions. The
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percentage increases in anaerobic glycolysis, lactate efflux and glycogen content were similar in control and
diabetic hearts in response to hypoxia, suggesting that diabetes does not impair the ability to upregulate
glucose metabolism and glucose uptake in response to hypoxia. There have been conflicting reports on
whether diabetes impairs cardiac metabolic flexibility, with some studies demonstrating metabolic
inflexibility in response to glucose infusion (Oakes et al., 2006), whereas other studies have reported
metabolic responsiveness to insulin (Hafstad et al., 2006). One advantage of probing metabolic flexibility
using hypoxia is that this stimuli is a key metabolic regulator that operates via a different mechanism, acting
through different pathways, to glucose and insulin. Our data would support that the diabetic heart retains
metabolic plasticity and can metabolically adapt to a chronic hypoxia stimulus. This is an important finding
in light of the growing interest in metabolic modulators for the treatment of the diabetic heart, as capacity to
change metabolism in diabetes is essential if these compounds have any potential to produce measureable
benefits. Thus, metabolic flexibility in diabetes may be a stimuli-specific phenomena, and targeting
metabolism pharmacologically may have to take into account which signalling pathways retain their function
in diabetes.
While the majority of metabolic parameters showed a hypoxic response of a similar direction or magnitude
between controls and diabetics, a few measurements displayed a significant interaction between the effects
of diabetes and hypoxia. Coronary flow, state 3-dependent mitochondrial respiration and state 4 oxidative
phosphorylation-independent oxygen consumption all showed more pronounced rates in diabetics following
hypoxia than in controls. This would suggest that, for these oxygen supplying and consuming pathways,
that diabetics have an abnormal response to hypoxia. Given that these parameters were normal in normoxic
diabetic hearts, our data demonstrates an as yet unidentified interplay between diabetes and hypoxic
adaptation that promotes the use of oxygen under hypoxic conditions.
In contrast to other studies (Marfella et al., 2002; Xue et al., 2012), we found no pre-existing differences in
HIF-1α mRNA or HIF targets genes or proteins in our diabetic hearts in normoxia.  Due to technical 
limitations we were unable to measure HIFα protein during hypoxia in our diabetic and control rats, however, 
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HIF target genes were not differentially activated in response to hypoxia in type 2 diabetic hearts compared
with controls, demonstrating that activation of this pathway in response to changes in oxygen concentration
were not modified in diabetes. Thus, changes in metabolism where interactions between diabetes and
hypoxia were found cannot be attributed to difference in activation of HIF1α signalling.  The contrast 
between other studies and our data may lie in the degree of hyperglycaemia in these animal models. It has
been reported in type 1 diabetic and db/db hearts, with plasma glucose concentrations ranging from 22-58
mmol/l, that normoxic HIF-1α mRNA was increased whereas downstream targets were decreased (Marfella
et al., 2002; Jesmin et al., 2007; Park et al., 2009). In cell culture experiments, incubating dermal fibroblasts
with 5.5 – 11 mmol/l glucose concentrations did not affect HIF activation in hypoxia, however,
concentrations of 25 – 30 mmol/l glucose suppressed the hypoxia-induced HIF accumulation (Catrina et al.,
2004). Thus, it is likely that the severity of diabetes and hyperglycaemia may play a key role in influencing
HIF signalling in the heart. Our model of type 2 diabetes was chosen to mimic human type 2 diabetes, with
mild hyperglycaemia, hyperinsulinaemia and hyperlipidaemia, and because it mimics the developmental
process of the disease (Mansor et al., 2013b). Therefore, in type 2 diabetes if adequate glucose control can
be maintained, defects in HIF and downstream signalling may not be present, and the ability to adapt to
hypoxia can be preserved.
While diabetic hearts retain the ability to adapt to hypoxia, in absolute terms they metabolise less glucose
anaerobically, store less glycogen and are more dependent on fatty acid and oxidative metabolism following
hypoxia than control hearts. This may have profound consequences if the hypoxia became more severe,
either acutely, as occurs in an infarct, or chronically, as can occur during post-infarction structural
remodelling or in sleep apnoea (Willam et al., 2006). Increased myocardial glycogen content would protect
the heart by providing an on-site glycolytic substrate during hypoxia, and higher glycogen reserves have
been associated with increased tolerance of ischemia (Cross et al., 1996). Similarly, myocardial work-
independent oxygen consumption has been shown to decrease in diabetic hearts when fatty acid oxidation is
suppressed (Boardman et al., 2009). Thus, the diabetic heart may be less metabolically prepared if the
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hypoxia were to escalate. Our data demonstrate that in response to an acute hypoxic insult the diabetic hearts
chronically adapted to hypoxia did significantly worse than the control hearts adapted to hypoxia. The
diabetic hearts decreased their function more rapidly and recovered it to a much less extent, demonstrating
a reduced tolerance of acute hypoxia. While a direct causal connection cannot be made by the current data,
a lower rate of glycolysis, lower glycogen content and elevated respiration rates may well contribute to this
functional deficit.
Control rats following chronic hypoxia had decreased glucose concentrations accompanied by elevated lipid
metabolites: NEFA, β-OHB and TAG.  This profile is in agreement with the changes in systemic metabolism, 
shifting towards metabolising more glucose and less fat in hypoxia, shown to occur at the whole body level
in both animal and humans (Stanley et al., 1990; Jun et al., 2012; Yao et al., 2013). Diabetic animals became
normoglycaemic in response to chronic hypoxia, likely a consequence of hypoxia-induced increase in
systemic glucose metabolism, however, they became more hyperlipidemic, hyperketonaemic and
hypoinsulinaemic than controls.  Activation of HIF-1α in pancreatic β-cells decreases insulin secretion 
(Cantley et al., 2009), and this may be more profound in our hyperinsulinaemic diabetic animals in which
the pancreas is already working harder. Thus, the more extreme lipid metabolite profile in diabetic rats
following hypoxia is likely the consequence of multiple factors: – the pre-existing hyperlipidaemic state of
diabetes, the hypoxia-induced suppression of systemic fat oxidation, and the hypoxia-induced decrease in
insulin secretion.
Myocardial fatty acid utilisation is promoted by the nuclear transcription factor PPARα, which is activated 
by elevated long chain fatty acid ligands, as occurs in the hyperlipidaemic state associated with diabetes and
insulin resistance.  In response to hypoxia, PPARα activation and transactivation of its targets genes are 
decreased (Huss et al., 2001; Belanger et al., 2007). Our data demonstrate that the diabetic hearts retains the
ability for hypoxia to downregulate PPARα targets, but that these genes are so highly activated under 
baseline normoxic conditions, that the hypoxia-induced change in most instances only brings down the
targets to the levels we find in a normoxic control heart. Hypoxia and diabetes are operating at either end of
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a PPARα “see-saw”, with hypoxia decreasing and diabetes increasing PPARα target proteins.  
Overactivation of PPARα has been shown to impair recovery following ischemia-reperfusion (Dewald et al.,
2005; Sambandam et al., 2006), and the ability to decrease PPARα signalling pathways is part of the response 
to cardiac disease, therefore, preventing this may be deleterious in the long term.
In conclusion, type 2 diabetic hearts retain metabolic flexibility to adapt to chronic hypoxia by increasing
glycolysis and decreasing fatty acid oxidation, associated with a normal HIF signalling system. However,
these hypoxia-induced changes were superimposed on a diabetic heart that was metabolically abnormal at
baseline, resulting in lower absolute rates of glycolysis, higher rates of fatty acid oxidation and oxygen
consumption in hypoxic diabetic hearts compared with hypoxic controls. These differences in metabolism
following adaptation to chronic hypoxia were associated with an impaired functional recovery of the diabetic
heart when exposed to an acute hypoxic insult.
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Figure Legends
Figure 1. Glycolytic rates, lactate efflux rates and glycogen content in control and diabetic hearts following
adaptation to chronic hypoxia or normoxia. * p < 0.05 vs. normoxia within same disease state, # p < 0.05
vs. control under same oxygen condition, n = 5 – 9 per group.
Figure 2. Fatty acid oxidation rates, myocardial triglycerides and citrate synthase activities in control and
diabetic hearts following adaptation to chronic hypoxia or normoxia. * p < 0.05 vs. normoxia within same
disease state, # p < 0.05 vs. control under same oxygen condition, n = 5 – 9 per group.
Figure 3. Mitochondrial respiration rates under ADP-stimulated state 3 and ADP-depleted state 4 conditions
in interfibrillar and subsarcolemmal mitochondria, from control and diabetic hearts following adaptation to
chronic hypoxia or normoxia. * p < 0.05 vs. normoxia within same disease state, # p < 0.05 vs. control under
same oxygen condition, † p < 0.05 interaction between hypoxia and diabetes, n = 4 – 8 per group.
Figure 4. Haematocrit, HIF and HIF-target genes, HIF-target enzymes and HIF protein, from control and
diabetic hearts following adaptation to chronic hypoxia or normoxia. * p < 0.05 vs. normoxia within same
disease state, # p < 0.05 vs. control under same oxygen condition, n = 5 – 12 per group.
Figure 5.  PPARα targets pyruvate dehydrogenase kinase 4, uncoupling protein 3, medium chain acyl-
coenzyme A dehydrogenase and fatty acid transport protein 1 protein and activity levels, from control and
diabetic hearts following adaptation to chronic hypoxia or normoxia. Protein levels of substrate transporters
GLUT4 and FAT/CD36, and PPARα mRNA from control and diabetic hearts following adaptation to chronic 
hypoxia or normoxia. * p < 0.05 vs. normoxia within same disease state, # p < 0.05 vs. control under same
oxygen condition, n = 5 – 8 per group.
Figure 6. Percentage recovery of rate pressure product following 32 minutes of acute hypoxia and 8 minutes
of reoxygenation, in chronically hypoxic control and diabetic hearts. # p < 0.05 vs hypoxic control, n = 3 –
4 per group.
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Normoxic
Control
Hypoxic
Control
Normoxic
Diabetic
Hypoxic
Diabetic
Starting body weight (g) 270 ± 13 270 ± 6 270 ± 8 265 ± 7
Terminal body weight (g) 380 ± 13 366 ± 5 395 ± 8 376 ± 10
Heart weight (g) 1.21± 0.09 1.34 ± 0.09 1.47 ± 0.06 # 1.52 ± 0.05
Heart weight to body
weight ratio (x10
3
)
3.14 ± 0.14 3.56 ± 0.19 3.66 ± 0.18 # 4.01 ± 0.10
Epididymal fat pad
weight (g)
5.91 ± 0.56 5.65 ± 0.75 10.26 ± 0.32 # 8.40 ± 0.37 #
Fat pad to body weight
ratio (x 10
2
)
1.46 ± 0.13 1.60 ± 0.19 2.59 ± 0.09 # 2.30 ± 0.12 #
Fasting plasma metabolites
Glucose (mmol/l) 6.18 ± 0.43 8.08 ± 0.61 #
Insulin (ug/l) 0.31 ± 0.03 0.44 ± 0.04 #
Plasma metabolites in the fed state
Glucose (mmol/l) 12.7 ± 0.3 10.1 ± 0.5 * 14.1 ± 0.3 # 11.5 ± 0.7 *
NEFA (mmol/l) 0.05 ± 0.01 0.11 ± 0.02 * 0.09 ± 0.01 # 0.15 ± 0.02 *
TAG (mmol/l) 1.44 ± 0.18 2.15 ± 0.27 * 1.18 ± 0.11 1.81 ± 0.19 *
Insulin (ug/l) 1.90 ± 0.26 1.56 ± 0.21 1.88 ± 0.22 1.11 ± 0.16 *
β-OHB (mmol/l) 0.32 ± 0.02 0.39 ± 0.01 * 0.57 ± 0.03 # 0.78 ± 0.04 *#†
* p < 0.05 vs. normoxia within same disease state, # p < 0.05 vs. control under same oxygen
condition, † p < 0.05 interaction between hypoxia and diabetes. Body weights n = 12 – 16, heart
weights n = 8 – 10, fat pads n = 4 – 8. Fasting metabolites obtained prior to entry into the hypoxia
chamber after 3 weeks (n = 5 – 9), fed metabolites after 6 weeks (n = 12 – 17). NEFA, non-esterified
fatty acids; β-OHB, β-hydroxybutyrate; TAG, triacylglycerol.
Table 1. Physical characteristics and plasma metabolites from control and diabetic rats housed in
normoxia or hypoxia
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Normoxic
Control
Hypoxic
Control
Normoxic
Diabetic
Hypoxic
Diabetic
Coronary flow rates
(ml/min)
18 ± 1 16 ± 1 18 ± 1 20 ± 1 #†
Developed pressure
(mmHg)
134 ± 2 149 ± 6 * 136 ± 6 149 ± 7
Heart rate (beats/min) 280 ± 8 258 ± 8 276 ± 10 277 ± 11
Rate pressure product
(mmHg/min x 10
3
)
38 ± 2 38 ± 1 38 ± 3 41 ± 1
* p < 0.05 vs. normoxia within same disease state, # p < 0.05 vs. control under
same oxygen condition, † p < 0.05 interaction between hypoxia and diabetes, n
= 7 – 10.
Table 2. Cardiac function from control and diabetic rats housed in normoxia or
hypoxia.
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Norxmoxic
Control
Hypoxic
Control
Normoxic
Diabetic
Hypoxic
Diabetic
ATP/ADP pool 2.54 ± 0.38 3.26 ± 0.77 2.45 ± 0.36 2.69 ± 1.17
Creatine 13.2 ± 1.4 11.2 ± 1.1 12.2 ± 0.8 9.7 ± 0.5 *
Succinate 0.61 ± 0.22 0.43 ± 0.38 0.63 ± 0.34 0.44 ± 0.23
Fumarate 0.04 ± 0.03 0.03 ± 0.01 0.03 ± 0.02 0.04 ± 0.01
Alanine 1.56 ± 0.18 1.59 ± 0.31 1.71 ± 0.31 1.45 ± 0.27
Glutamate 5.96 ± 0.65 6.43 ± 1.00 6.52 ± 0.39 6.23 ± 0.80
Glutamine 6.32 ± 0.55 6.58 ± 0.93 6.96 ± 0.77 7.59 ± 2.16
Glycine 0.44 ± 0.06 0.51 ± 0.06 0.56 ± 0.12 0.60 ± 0.12
Aspartate 1.35 ± 0.17 1.36 ± 0.08 1.87 ± 0.33 2.41 ± 0.45 #
NAD
+ 0.49 ± 0.04 0.63 ± 0.10 0.58 ± 0.06 0.81 ± 0.15
Table 3. Cardiac metabolites from control and diabetic rats housed in normoxia or hypoxia.
Units are µmol/gww. * p < 0.05 vs. normoxia within same disease state, # p < 0.05 vs.
control under same oxygen condition, n = 4 – 5.
Table 1
Normoxic
Control
Hypoxic
Control
Normoxic
Diabetic
Hypoxic
Diabetic
Starting body weight (g) 270 ± 13 270 ± 6 270 ± 8 265 ± 7
Terminal body weight (g) 380 ± 13 366 ± 5 395 ± 8 376 ± 10
Heart weight (g) 1.21± 0.09 1.34 ± 0.09 1.47 ± 0.06 # 1.52 ± 0.05
Heart weight to body
weight ratio (x103)
3.14 ± 0.14 3.56 ± 0.19 3.66 ± 0.18 # 4.01 ± 0.10
Epididymal fat pad
weight (g)
5.91 ± 0.56 5.65 ± 0.75 10.26 ± 0.32 # 8.40 ± 0.37 #
Fat pad to body weight
ratio (x 102)
1.46 ± 0.13 1.60 ± 0.19 2.59 ± 0.09 # 2.30 ± 0.12 #
Fasting plasma metabolites
Glucose (mmol/l) 6.18 ± 0.43 8.08 ± 0.61 #
Insulin (ug/l) 0.31 ± 0.03 0.44 ± 0.04 #
Plasma metabolites in the fed state
Glucose (mmol/l) 12.7 ± 0.3 10.1 ± 0.5 * 14.1 ± 0.3 # 11.5 ± 0.7 *
NEFA (mmol/l) 0.05 ± 0.01 0.11 ± 0.02 * 0.09 ± 0.01 # 0.15 ± 0.02 *
TAG (mmol/l) 1.44 ± 0.18 2.15 ± 0.27 * 1.18 ± 0.11 1.81 ± 0.19 *
Insulin (ug/l) 1.90 ± 0.26 1.56 ± 0.21 1.88 ± 0.22 1.11 ± 0.16 *
β-OHB (mmol/l) 0.32 ± 0.02 0.39 ± 0.01 * 0.57 ± 0.03 # 0.78 ± 0.04 *#†
* p < 0.05 vs. normoxia within same disease state, # p < 0.05 vs. control under same oxygen
condition, † p < 0.05 interaction between hypoxia and diabetes. Body weights n = 12 – 16, heart
weights n = 8 – 10, fat pads n = 4 – 8. Fasting metabolites obtained prior to entry into the
hypoxia chamber after 3 weeks (n = 5 – 9), fed metabolites after 6 weeks (n = 12 – 17). NEFA,
non-esterified fatty acids; β-OHB, β-hydroxybutyrate; TAG, triacylglycerol.
Table 1. Physical characteristics and plasma metabolites from control and diabetic rats housed in
normoxia or hypoxia
Table 2
Normoxic
Control
Hypoxic
Control
Normoxic
Diabetic
Hypoxic
Diabetic
Coronary flow rates
(ml/min)
18 ± 1 16 ± 1 18 ± 1 20 ± 1 #†
Developed pressure
(mmHg)
134 ± 2 149 ± 6 * 136 ± 6 149 ± 7
Heart rate (beats/min) 280 ± 8 258 ± 8 276 ± 10 277 ± 11
Rate pressure product
(mmHg/min x 103)
38 ± 2 38 ± 1 38 ± 3 41 ± 1
* p < 0.05 vs. normoxia within same disease state, # p < 0.05 vs. control under
same oxygen condition, † p < 0.05 interaction between hypoxia and diabetes, n
= 7 – 10.
Table 2. Cardiac function from control and diabetic rats housed in normoxia or
hypoxia.
Norxmoxic
Control
Hypoxic
Control
Normoxic
Diabetic
Hypoxic
Diabetic
ATP/ADP pool 2.54 ± 0.38 3.26 ± 0.77 2.45 ± 0.36 2.69 ± 1.17
Creatine 13.2 ± 1.4 11.2 ± 1.1 12.2 ± 0.8 9.7 ± 0.5 *
Succinate 0.61 ± 0.22 0.43 ± 0.38 0.63 ± 0.34 0.44 ± 0.23
Fumarate 0.04 ± 0.03 0.03 ± 0.01 0.03 ± 0.02 0.04 ± 0.01
Alanine 1.56 ± 0.18 1.59 ± 0.31 1.71 ± 0.31 1.45 ± 0.27
Glutamate 5.96 ± 0.65 6.43 ± 1.00 6.52 ± 0.39 6.23 ± 0.80
Glutamine 6.32 ± 0.55 6.58 ± 0.93 6.96 ± 0.77 7.59 ± 2.16
Glycine 0.44 ± 0.06 0.51 ± 0.06 0.56 ± 0.12 0.60 ± 0.12
Aspartate 1.35 ± 0.17 1.36 ± 0.08 1.87 ± 0.33 2.41 ± 0.45 #
NAD+ 0.49 ± 0.04 0.63 ± 0.10 0.58 ± 0.06 0.81 ± 0.15
Table 3. Cardiac metabolites from control and diabetic rats housed in normoxia or hypoxia.
Units are µmol/gww. * p < 0.05 vs. normoxia within same disease state, # p < 0.05 vs.
control under same oxygen condition, n = 4 – 5.
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Real-time quantitative PCR primers
Target NM Primer sequence
Heme oxygenase 1 NM_012580.2 Fp: GTC-AGG-TGT-CCA-GGG-AAG-G
Rp: CTC-TTC-CAG-GGC-CGT-ATA-GA
VEGF NM_031836.2 Fp: CAA-GCC-AAG-GCG-GTG-AGC-CA
Rp: TCT-GCC-GGA-GTC-TCG-CCC-TC
PHD3 NM_019371.1 Fp: CTA-TGT-CAA-GGA-GCG-GTC-CAA
Rp: GTC-CAC-ATG-GCG-AAC-ATA-ACC
HIF1α NM_024359.1 Fp: TGC-TTG-GTG-CTG-ATT-TGT-GA
Pp: GGT-CAG-ATG-ATC-AGA-GTC-CA
GAPDH NM_017008 FP: TGG-GAA-GCT-GGT-CAT-CAA-C
Rp: GCA-TCA-CCC-CAT-TTG-ATG-TT
Cyclophilin A NM_017101.1 Fp: CTG-ATG-GCG-AGC-CCT-TG
Rp: TCT-GCT-GTC-TTT-GGA-ACT-TTG-TC
RPL13A NM_173340.2 Fp: CCC-TCC-ACC-CTA-TGA-CAA
Rp: GGT-ACT-TCC-ACC-CGA-CCT-C
HMBS NM_013168.2 Fp: TCC-CTG-AAG-GAT-GTG-CCT-AC
Rp: ACA-AGG-GTT-TTC-CCG-TTT-G
HPRT1 NM_012583.2 Fp: GAC-CGG-TTC-TGT-CAT-GTC-G
Rp: ACC-TGG-TTC-ATC-ATC-ACT-AAT-CAC
Western blotting antibodies
Target Supplied by:
GLUT4 Prof. Geoff Holman, University of Bath, UK
PDK4 Prof. Mary Sugden, Queen Mary’s, University of London, UK
FAT/CD36 Dr Narendra Tandon, Otsuka Maryland Medicinal Labs, USA
Cyclophilin B Abcam
UCP3 Abcam
FATP1 Santa Cruz Biotechnology
HIF-1α Novus Biologicals
Supplementary Table 1
Supplementary Table1. Real-time quantitative PCR primers and western blotting primary
antibodies
GAPDH; glyceraldehyde-3-phosphate dehydrogenase, RP13A; ribosomal protein L13A,
HMBS; hydroxymethylbilane synthase, HPRT1; hypoxanthine phosphoribosyltransferase 1.
Significant effect
of hypoxia
Significant effect
of diabetes
Interaction
Heart weight 0.003
Heart to body weight ratio 0.017 0.003
Fat pad weight 0.000
Fat pad to body weight ratio 0.000
Glucose 0.000 0.004
NEFA 0.000 0.01
TAG 0.000
Insulin 0.013
Β-OHB 0.000 0.000 0.000
Coronary flow rates 0.025 0.004
Developed pressure 0.013
Glycolytic rates 0.000 0.000
Lactate efflux rates 0.002 0.000
Glycogen 0.002 0.003
Fatty acid oxidation rates 0.004 0.000
Myocardial triglycerides 0.049
Citrate synthase activity 0.048 0.014
Creatine 0.043
Aspartate 0.004
State 3 IFM respiration 0.015 0.004
State 3 SSM respiration 0.013 0.045
State 4 IFM respiration 0.005 0.001 0.03
Haematocrit 0.000
Prolyl hydroxylase 3 mRNA 0.000
Heme oxygenase 1 mRNA 0.000
Aconitase activity 0.000
PDK4 protein 0.024 0.000
UCP3 protein 0.013 0.024
MCAD activity 0.000 0.000
FATP1 protein 0.008
GLUT4 protein 0.032
FAT/CD36 protein 0.001
Supplementary Table 2. Two way ANOVA p values for the effects of hypoxia, diabetes and
interactions between the two, for metabolic measurements.
Supplementary Table 3
Normoxic
Control
Hypoxic
Control
Normoxic
Diabetic
Hypoxic
Diabetic
Palmitoyl CoA respiration (nmol O2/min/mg mitochondrial protein)
State 3 181 ± 6 131 ± 7 * 155 ± 9 161 ± 14 †
State 4 43 ± 3 40 ± 7 39 ± 4 36 ± 4
Max ADP 244 ± 8 181 ± 18 * 228 ± 17 205 ± 19
RCR 4.4 ± 0.3 3.5 ± 0.5 4.1 ± 0.3 4.6 ± 0.3
Pyruvate respiration (nmol O2/min/mg mitochondrial protein)
State 3 260 ± 9 210 ± 12 * 213 ± 11 # 216 ± 10 †
State 4 48 ± 4 42 ± 6 36 ± 3 39 ± 2
Max ADP 229 ± 15 219 ± 18 213 ± 18 210 ± 11
RCR 5.5 ± 0.4 5.2 ± 0.5 6.1 ± 0.6 5.6 ± 0.6
Glutamate respiration (nmol O2/min/mg mitochondrial protein)
State 3 207 ± 11 204 ± 15 188 ± 8 202 ± 13
State 4 24 ± 1 27 ± 4 23 ± 2 24 ± 3
Max ADP 241 ± 7 222 ± 29 209 ± 9 219 ± 12
RCR 8.7 ± 0.3 7.9 ± 1.1 8.5 ± 1.0 8.5 ± 0.9
Succinate respiration (nmol O2/min/mg mitochondrial protein)
State 3 311 ± 21 256 ± 23 296 ± 17 264 ± 7
State 4 81 ± 7 87 ± 10 93 ± 8 133 ± 6 *#†
RCR 3.9 ± 0.2 3.0 ± 0.3 * 3.3 ± 0.3 2.0 ± 0.1 *#
FCCP-
uncoupled
248 ± 9 194 ± 15 * 239 ± 15 203 ± 3 *
* p < 0.05 vs. normoxia within same disease state, # p < 0.05 vs. control under same
oxygen condition, † p < 0.05 interaction between hypoxia and diabetes. RCR,
respiratory control ratio, n = 4 - 8.
Supplementary Table 3. Mitochondrial state 4 and maximal ADP-stimulated
respiration in cardiac interfibrillar mitochondria from control and diabetic rats
housed in normoxia or hypoxia.
Supplementary Table 4
Normoxic
Control
Hypoxic
Control
Normoxic
Diabetic
Hypoxic
Diabetic
Palmitoyl CoA respiration (nmol O2/min/mg mitochondrial protein)
State 3 116 ± 4 86 ± 10 * 105 ± 5 101 ± 13 †
State 4 25 ± 3 35 ± 3 27 ± 1 29 ± 4
Max ADP 138 ± 4 120 ± 7 133 ± 5 123 ± 7
RCR 4.2 ± 0.2 3.0 ± 0.3 3.9 ± 0.2 4.0 ± 0.8
Pyruvate respiration (nmol O2/min/mg mitochondrial protein)
State 3 162 ± 7 148 ± 10 139 ± 3 # 145 ± 11
State 4 35 ± 2 38 ± 3 29 ± 3 32 ± 4
Max ADP 134 ± 9 140 ± 8 139 ± 6 143 ± 7
RCR 4.6 ± 0.2 3.9 ± 0.1 5.0 ± 0.5 4.5 ± 0.3
Glutamate respiration (nmol O2/min/mg mitochondrial protein)
State 3 112 ± 6 113 ± 12 94 ± 3 109 ± 8
State 4 19 ± 2 22 ± 2 17 ± 1 21 ± 1
Max ADP 140 ± 6 139 ± 16 118 ± 3 # 133 ± 7
RCR 6.2 ± 0.5 5.1 ± 0.4 5.7 ± 0.3 5.2 ± 0.3
Succinate respiration (nmol O2/min/mg mitochondrial protein)
State 3 193 ± 13 178 ± 14 179 ± 9 168 ± 6
State 4 54 ± 3 63 ± 6 62 ± 7 75 ± 7
RCR 3.5 ± 0.1 2.9 ± 0.3 * 2.8 ± 0.3 # 2.3 ± 0.3
Maximal FCCP-
uncoupled
155 ± 6 134 ± 11 146 ± 9 123 ± 2 *
* p < 0.05 vs. normoxia within same disease state, # p < 0.05 vs. control under
same oxygen condition, † p < 0.05 interaction between hypoxia and diabetes,
RCR, respiratory control ratio, n = 4 - 8.
Supplementary Table 4. Mitochondrial state 3, state 4 and maximal ADP-
stimulated respiration in cardiac subsarcolemmal mitochondria from control
and diabetic rats housed in normoxia or hypoxia.
